Research ArticleArticle

Concurrent Flavin-Containing Monooxygenase Down-Regulation and Cytochrome P-450 Induction by Dietary Indoles in Rat: Implications for Drug-Drug Interaction

Sirinmas Katchamart, David M. Stresser, Shangara S. Dehal, David Kupfer and David E. Williams
Drug Metabolism and Disposition August 2000, 28 (8) 930-936;

Abstract

Our laboratory has previously shown that dietary administration of indole-3-carbinol (I3C) to male Fischer 344 rats has the very unusual property of inducing hepatic levels of a number of cytochrome P450s (CYPs), especially CYP1A1, while markedly inhibiting the levels of flavin-containing monooxygenase (FMO) 1 protein and its catalytic activity. We hypothesized that rats fed I3C or 3,3′-diindolylmethane (DIM), one of its major acid condensation products formed in vivo, should exhibit a marked shift in the metabolic profiles of drugs or xenobiotics that are substrates for both monooxygenase systems. Male rats were fed AIN-76A powdered diets containing 0, 1000, or 2500 ppm I3C or DIM for 4 weeks. Dietary I3C and DIM reduced FMO1 protein levels (8% reduction with I3C and 84% with DIM at 1000 ppm, and 90% reduction with I3C and 97% with DIM at 2500 ppm) in hepatic microsomes. The ratio of FMO (N-oxygenation)- to CYP (N-demethylation)-mediated metabolism ofN,N-dimethylaniline decreased in liver microsomes from I3C- or DIM-fed rats from near unity to 0.02 at the highest dietary doses. FMO-mediated N-oxygenation (nicotine N-1′-oxide) was decreased, whereas CYP-mediated (nornicotine and nicotine Δ 1,5-iminium ion) metabolism of nicotine was unchanged in liver microsomes from rats fed I3C or DIM. Similarly, the ratio of FMO to CYP metabolites of tamoxifen decreased due to a reduction in N-oxygenation. This study demonstrates alteration of FMO- and CYP-mediated drug metabolism in vitro by dietary I3C or DIM and suggests the potential for altered toxicity of tamoxifen and nicotine in vivo.

Indole glucosinolate (glucobrassicin) is the most abundant of all glucosinolates and is found in high concentrations in cruciferous vegetables such as broccoli, cabbage, cauliflower, and Brussels sprouts. The glucosinolate hydrolysis products from myrosinase (thioglucoside glycohydrolase EC 3:2:3:1) at neutral pH are glucose, sulfate, 3-indolylmethyl isothiocyanate, indole-3-carbinol (I3C),2and thiocyanate ion. I3C may condense to 3,3′-diindolylmethane (DIM) and higher molecular weight oligomers or reacts with ascorbic acid to form ascorbigen (McDanell et al., 1988). A number of studies have shown I3C to be chemoprotective against cancer in multiple target organs such as mammary tissue (Grubbs et al., 1995), liver (Bailey et al., 1991), endometrium (Kojima et al., 1994), lung (Morse et al., 1990), and colon (Guo et al., 1995) in animal models. I3C has been proposed for chemoprevention of breast cancer in healthy women (Wong et al., 1997). Both I3C and DIM are marketed to the public as dietary supplements.

There are many proposed mechanisms involved in the anticarcinogenic activity of I3C, including alteration of phase I and phase II enzymes (Stresser et al., 1994a,b), free radical scavenging (Arnao et al., 1996), and alteration of the cell cycle, resulting in the G1 arrest of breast cancer cells (Cover et al., 1998). However, the anticarcinogenic activity of I3C depends on the timing of I3C treatment. Chemoprotection is observed when I3C is given before and/or during carcinogenic exposure (Wattenberg, 1977). Long-term postinitiation exposure can result in tumor promotion (Bailey et al., 1987).

Under the low pH conditions of the stomach, I3C undergoes a series of condensation reactions resulting in the production of various dimers, linear and cyclic trimers, and tetramers (Bjeldanes et al., 1991). A major product in vivo after oral administration of I3C (Stresser et al., 1995b) and in vitro (Spande, 1979) is DIM. When DIM is coinjected with aflatoxin B1, it reduces hepatic aflatoxin B1-DNA binding and tumor incidence in rainbow trout embryos (Dashwood et al., 1994). DIM is a potent nonspecific inhibitor of rat and human cytochrome P450 (CYP) 1A1, human CYP1A2, and rat CYP2B1 (Stresser et al., 1995a). Chen et al. (1998) showed that DIM was an aryl hydrocarbon receptor ligand and induced CYP1A1 in MCF-7 cells at a concentration of 100 μM. DIM also inhibited E2-induced proliferation of MCF-7 cells and down-regulated the nuclear estrogen receptor. 7,12-Dimethylbenz[a]anthracene-induced mammary tumor growth in Sprague-Dawley rats was inhibited by DIM at a dose of 5 mg/kg given every other day under conditions in which no induction of hepatic CYP1A1 was observed.

Our laboratory has previously shown that I3C administered in the diet to male Fischer 344 rats has the very unusual property of inducing hepatic levels of a number of CYPs, especially CYP1A, while markedly inhibiting flavin-containing monooxygenase (FMO) 1 in both a dose- and time-dependent manner (Larsen-Su and Williams, 1996). In this study, we report that I3C and DIM each induced CYP1A1/1A2 and inhibited the expression and activity of FMO1 in liver of male rats. Simultaneously, they exhibited a marked shift in the metabolic profiles of xenobiotics such as N,N-dimethylaniline (DMA) and drugs such as tamoxifen and nicotine, which are substrates for both monooxygenases. Alteration of the FMO/CYP ratio may have marked effects on toxicological and/or therapeutic properties, depending on the drug or xenobiotic.

Materials and Methods

Chemicals and Diet.

I3C was purchased from Aldrich Chemical Co. (Milwaukee, WI). DIM was the gift of BioResponse L.L.C. (Boulder, CO). I3C and DIM were incorporated into powdered semisynthetic AIN-76A diet prepared without preservatives. The diet was prepared just before initiation of the experiment and stored frozen until the day before feeding. DMA (15.5 mCi/mmol, UL-ring) was purchased from Sigma Chemical Co. (St. Louis, MO). [3H-N-methyl]Tamoxifen (85.6 Ci/mmol) was obtained from DuPont-NEN (Boston, MA). (S)-5-3H-Nicotine (32 Ci/mmol), prepared by the catalytic tritiation of (S)-5-bromonicotine (Shigenaga et al., 1987) was a gift from Dr. Mark Shigenaga.

Animals.

Four-week-old male Fischer 344 rats were acclimated to AIN-76A diet for 7 days before being switched to AIN-76A diet containing I3C or DIM at levels of 0, 1000, or 2500 ppm and fed ad libitum for 4 weeks. The rats were sacrificed by CO2 asphyxiation, and livers were removed, frozen in liquid N2, and stored at −80°C until analysis. The protocols used were approved by the Oregon State University Institutional Animal Care and Use Committee.

Microsome Preparation and Immunodetection of FMO1.

Liver microsomes were prepared by ultracentrifugation according toGuengerich (1989). Protein was measured by the method of Lowry et al. (1951). The liver microsomal proteins were separated by SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to nitrocellulose membranes (Towbin et al., 1979). The blots were probed with a polyclonal antibody specific to pig liver FMO1 (a generous gift from Dr. Daniel Ziegler, University of Texas at Austin), followed with a goat anti-rabbit secondary antibody conjugated to horseradish peroxidase (Bio-Rad, Richmond, CA) and then visualized using a chemiluminescence kit (Amersham Corp., Arlington Heights, IL). Quantitation was performed by densitometry, using an HP ScanJet IIcx flatbed scanner and NIH Image software version 1.54 (public domain, Wayne Rasband, National Institutes of Health, Bethesda, MD).

DMA N-Oxygenation.

FMO and CYP activity toward [14C]DMA was determined using an HPLC assay with a reverse-phase ACT-1 column and radiochemical detection (Williams, 1991; Shehin-Johnson et al., 1995). FMO-mediated N-oxygenation and CYP-mediatedN-demethylation can be determined simultaneously by this method.

Nicotine Metabolism.

Nicotine metabolism was assayed according to Williams et al. (1990a). Nicotine, nicotine N-1′-oxide, nornicotine, and nicotine Δ1,5-iminium metabolites are readily resolved using a Beckman Ultrasphere C18 ODS (5 μm, 4.6 mm × 25 cm) column with quantification via on-line radiochemical detection.

Tamoxifen Metabolism.

The incubations, containing rat liver microsomes, radiolabeled tamoxifen, and an NADPH-regenerating system in phosphate buffer (pH 7.4), were carried out as previously described (Dehal and Kupfer, 1997). After a 1-h incubation, the reaction was terminated, and metabolites resolved on silica gel thin-layer chromatography plates (Whatman, Inc., Clifton, NJ) with CHCl3/CH3OH/NH4OH (80:20:0.5, v/v/v). Radiolabeled metabolites on thin-layer chromatography were analyzed and quantified by radioscanning using the System 2000 imaging scanner (Bioscan, Inc., Washington, DC).

Statistical Analysis.

Statistical analyses of the data were performed using Student'st test. All data points are the mean ± S.D. for six rats per group. P values less than .05 were considered significant.

Results

Dietary administration for 4 weeks of I3C or DIM (Fig.1) to male Fischer 344 rats resulted in a dose-dependent reduction in liver microsomal FMO1 protein levels (Fig.2) as previously reported by our laboratory for I3C (Larsen-Su and Williams, 1996). The higher dose of I3C, 2500 ppm, reduced FMO1 protein levels to 10% that of controls. DIM was markedly more potent than I3C, reducing FMO1 levels to 16 and 3% of controls at 1000 and 2500 ppm, respectively.

Figure 1
Figure 1

Chemical structures of I3C, DIM, DMA, nicotine, and tamoxifen.

Figure 2
Figure 2

Western blotting analysis of FMO1 protein levels in liver microsomes from rats treated with I3C or DIM at doses of 1000 and 2500 ppm for 4 weeks.

*, indicates significantly lower than controls at P < .05. FMO1 blots are shown at top right. A, control; B, 1000 ppm I3C; C, 1000 ppm DIM; D, 2500 ppm I3C; and E, 2500 ppm DIM. Lanes 1 to 3, 0.5, 0.9, and 1.8 pmol of purified pig liver FMO1; lanes 4 to 9, rat liver microsomes. Protein load per lane: 20 μg for control, 20 μg for 1000 ppm I3C, 40 μg for 1000 ppm DIM, 40 μg for 2500 ppm I3C, and 40 μg 2500 ppm DIM.

DMA metabolism documents clearly the effects of I3C and DIM on FMO- and CYP-monooxygenation in liver microsomes of rats after dietary administration (Fig. 3). FMO-dependent formation of the N-oxide is inhibited in a dose-dependent manner; concurrently, CYP-dependent N-demethylation is induced. Consistent with the Western blotting results, DIM proved to be more potent than I3C; the higher dose of I3C reducedN-oxygenation of DMA to 28% of control levels, whereas the inhibition with DIM was to 7% of control levels. CYP-dependentN-demethylation was induced 3- to 5-fold, but the effect was not dose-dependent. The ratio of FMO/CYP metabolism of DMA decreased by 50-fold at the higher dose of DIM.

Figure 3
Figure 3

FMO-dependent N-oxygenation (filled columns) and CYP-dependent N-demethylation (hatched columns) of DMA in liver microsomes from rats treated with I3C or DIM at doses of 1000 and 2500 ppm for 4 weeks.

N-oxygenation was significantly (P < .05) decreased and N-demethylation significantly increased at all dietary levels of I3C and DIM.

Although the major CYP-mediated pathways of (S)-nicotine metabolism, N-demethylation to nornicotine, and formation of the Δ1,5-iminium ion, were unchanged by dietary I3C or DIM, FMO-catalyzed N-oxygenation of nicotine was markedly reduced (Fig. 4).

Figure 4
Figure 4

CYP- and FMO-mediated metabolism of3H-(S)-nicotine.

Liver microsomes from rats fed 0, 1000, or 2500 ppm I3C or DIM for 4 weeks were incubated with 3H-(S)-nicotine and the major metabolites nornicotine, nicotine Δ1,5-iminium ion (CYP, hatched columns), and nicotine N-1′-oxide (FMO, filled columns), resolved, and quantified by HPLC as described under Materials and Methods.

As was the case with nicotine, dietary exposure of rats to I3C and DIM markedly reduced the N-oxygenation of tamoxifen by liver microsomes without a marked increase in CYP-dependentN-demethylation and 4-hydroxylation (Fig.5).

Figure 5
Figure 5

FMO-mediated tamoxifen (TAM) N-oxide and CYP-mediated 4-hydroxy TAM and N-desmethyl TAM formation by liver microsomes from rats treated with I3C or DIM at doses of 1000 and 2500 ppm for 4 weeks.

*, indicates significantly lower than controls at P < .01.

Discussion

Our laboratory and others have documented that dietary exposure of I3C to rats induces a number of CYP isoforms. CYP1A1 is induced by greater than 20-fold, whereas more modest increases of 2- to 4-fold are observed for CYP1A2, CYP2B1/2, and CYP3A (Bradfield and Bjeldanes, 1987; Bjeldanes et al., 1991; Wortelboer et al., 1992a,b; Stresser et al., 1994a; Manson et al., 1998). Concurrent with this up-regulation of CYP-dependent metabolic pathways in the rat, the levels of FMO1 protein and FMO-dependent catalytic activity is markedly inhibited by dietary I3C in a dose- and time-dependent fashion (Larsen-Su and Williams, 1996).

Based on these findings, we postulated that dietary I3C exposure could significantly alter the metabolic profile of drugs and xenobiotics that are substrates for both monooxygenase systems. The three compounds chosen in this study to test this hypothesis, DMA, nicotine, and tamoxifen, are all tertiary amines. Tertiary aliphatic amines are typically excellent substrates for FMO, yielding the water-soluble and usually nontoxic N-oxide metabolites (Ziegler, 1993). Tertiary aliphatic amines are preferentially N-demethylated by CYP; in only rare cases in which α-hydrogens are absent does CYP produce N-oxides in significant amounts (Guengerich and MacDonald, 1984; Williams et al., 1989).

In the case of DMA, although Hlavica and Kunzel-Mulas (1993) found that CYP2B4-dependent superoxide anion radical production led to DMA-N-oxide production, others studies have found that, relative to FMO, this pathway is insignificant (Pandey et al., 1989;Seto and Guengerich, 1993). In this study, DMA-N-oxygenation was inhibited by dietary I3C in a dose-dependent manner.N-demethylation, presumably mediated predominantly by CYP2B1, was enhanced 3- to 5-fold, consistent with our previous documentation of CYP2B1/2 induction by dietary I3C in these rats (Stresser et al., 1994a). The pattern of inhibition of DMA-N-oxygenation (Fig. 3) closely resembled that of FMO1 protein repression (Fig. 2). At the higher dose of DIM, greater than 90% of DMA-N-oxygenation was inhibited. The relative contribution of CYP- and FMO- mediated metabolism of DMA is thus dramatically altered and serves as an example of how I3C and DIM could alter the therapeutic efficacy and/or toxicity of drugs or xenobiotics that are substrates for both monooxygenases.

Pretreatment with either I3C or DIM in the diet also altered the in vitro liver microsomal metabolic profile of (S)-nicotine. CYP-dependent N-demethylation to nornicotine and formation of the nicotine-Δ1′,5′-iminium ion were unaffected, whereas yield of the FMO-catalyzed nicotineN-1′-oxide was reduced to at or below the limits of detection.

Previous studies have demonstrated that the CYP2A and 2B subfamilies are active toward nicotine. In rabbit nasal tissue, CYP2A10/11 (P450 NMa) exhibited high activity toward nicotine (Williams et al., 1990b). In rat liver, phenobarbital treatment markedly enhances nicotine C-oxidation, due to induction of CYP2B1 (Hammond et al., 1991). The rabbit ortholog in lung, CYP2B4, is also the major nicotine oxidase in that organ (Williams et al., 1990a). In human liver, CYP2A6 is the major isoform catalyzing C-oxidation of nicotine (Berkman et al., 1995;Nakajima et al., 1996; Messina et al., 1997). Based on the modest induction of CYP 2B1/2 by I3C in the rat liver, it is somewhat surprising that we saw no induction of C-oxidation.

Nicotine is oxygenated at the N-1′ position by FMO1 and FMO3 (Damani et al., 1988; Cashman et al., 1992; Park et al., 1993). The stereoselective production of (S)-nicotine trans N-1′-oxide has been proposed as a mechanism for phenotyping individuals for liver FMO3 (Park et al., 1993). The virtual elimination of this pathway in liver microsomes from rats fed high concentrations of I3C and DIM is consistent with the down-regulation of FMO1 protein and DMA N-oxygenation discussed above. It could be speculated that I3C or DIM inhibition of nicotine-N-1′-oxide production in vivo could alter the pharmacokinetics of nicotine and provide protection against nicotine addiction and reduce the number of cigarettes smoked in a manner analogous to that seen with the polymorphism, which results in nonfunctional CYP2A6 (Pianezza et al., 1998). It has been observed that trimethylaminuria (a genetic defect in FMO3) patients exhibit impaired nicotine N-1′-oxygenation (Ayesh et al., 1988). One major caveat to this hypothesis involves the question of whether or not human liver FMO3 responds to dietary I3C and DIM as does rat liver FMO1.

Tamoxifen, an antiestrogen, is the therapeutic drug most often used in the treatment of breast cancer (Jordan, 1993) and, based on the results of a recent large clinical trial, is advocated as a chemopreventive agent for women at high risk of developing breast cancer (Fisher et al., 1998). Of concern with the long-term use of tamoxifen is an enhanced incidence of endometrial cancers (Killackey et al., 1985) and the observation that it is hepatocarcinogenic in the rat (Williams et al., 1993). Tamoxifen is bioactivated by CYPs to yield 4-hydroxytamoxifen, which is markedly more potent as an antiestrogen than the parent compound (Jordan et al., 1977). Another major CYP metabolite is N-desmethyl tamoxifen. Further hydroxylation of 4-hydroxytamoxifen results in the formation of tamoxifen catechol, a redox-active metabolite that covalently binds to macromolecules (Dehal and Kupfer, 1999). The major CYPs active toward tamoxifen and 4-hydroxytamoxifen are CYP3A4, 2D6, and 2C9 (Crewe et al., 1997; Dehal and Kupfer, 1997). N-oxygenation of tamoxifen is mediated by FMO, and the N-oxide is found in the serum of women taking the drug (Mani et al., 1993; Poon et al., 1995).

In this study we document a significant reduction in theN-oxygenation of tamoxifen catalyzed by liver microsomes of rats fed I3C or DIM. In liver microsomes from control rats, the ratio of CYP-mediated N-demethylation and 4-hydroxylation to FMO-mediated N-oxygenation is approximately unity; at the higher dose of I3C and both doses of DIM, the ratio increases to 3 to 4. A reduction in N-oxygenation may actually decrease tamoxifen toxicity. Previous work has provided evidence that FMO activity could enhance tamoxifen-dependent covalent binding (Mani and Kupfer, 1991). Recent studies document that tamoxifenN-oxide and metabolites covalently bind to DNA, and the authors state that there is evidence for dG-N2-tamoxifen N-oxide DNA adducts in humans (Umemoto et al., 1999). Based on these findings, we hypothesize that if a similar alteration occurs in humans, women taking tamoxifen in concert with diets high in cruciferous vegetables and/or taking I3C supplements could modulate their risk of developing toxic side effects.

As mentioned above, whether or not these studies with rat can be extrapolated to humans could depend, in large part, on whether or not down-regulation of human liver FMO3 is analogous to rat FMO1. Humans fed 300 g/day of Brussels sprouts, providing an estimated dose of 0.002 to 0.014 mmol of I3C/kg/day, exhibited a significant decrease in urinary trimethylamine N-oxide, presumably due to the inhibition of liver FMO3 (Cashman et al., 1999). This dose is markedly lower than the highest inhibitory dose of dietary I3C (0.46 mmol/kg/day) given to rats in this study. It must be kept in mind, however, that Brussels sprouts contain numerous other phytochemicals including isothiocyanates and dithiolanes that may effect FMO.

It may not be necessary for FMO3 protein to be down-regulated by I3C (as is the case with rat liver and intestinal FMO1) to observe inhibition, as we have found that I3C acid condensation products can directly inhibit FMO catalytic activity. DIM and indole[3,2-b]carbazole (ICZ) inhibited the catalytic activity of rat FMO1 in vitro with Kivalues of 47 and 31 μM, respectively (Larsen-Su, 1998). ICZ, DIM, and I3C also directly inhibit the catalytic activity of the major FMO in human liver, FMO3, with Ki values in the low micromolar range (Cashman et al., 1999). Of these three compounds, only DIM would be expected to be present in liver after I3C oral administration at levels capable of eliciting this response. Studies following the pharmacokinetics of 3H-I3C after oral administration to rats found no I3C in liver, and ICZ levels were estimated to be 1.6 nM; however, DIM levels were estimated to be 3 to 6 μM (Stresser et al., 1995b). Interestingly, DIM also directly inhibits rat and human CYP1A1, human CYP1A2, and rat CYP2B1 withKi values again in the low micromolar range (Stresser et al., 1995a). In this study, DIM was demonstrably more effective than I3C. The 1000 and 2500 ppm diets correspond to 6.2 and 15.5 mmols/kg for I3C and 4.1 and 10.2 mmol/kg for DIM; therefore, DIM was even more effective on a per mole basis.

In summary, we have demonstrated that administration of the indoles I3C and DIM, present in cruciferous vegetables and sold as dietary supplements, markedly alter the metabolism of drugs that are substrates for both CYP and FMO monooxygenases. Dietary I3C and DIM down-regulate the expression of FMO1 protein. Furthermore, DIM is capable of directly inhibiting the catalytic activity of FMO1 and FMO3 as well as a number of CYPs. These findings demonstrate the potential for previously unrecognized drug-drug interactions. The potential alterations in tamoxifen efficacy or nicotine toxicity in humans, as a result of a diet high in crucifers or through dietary supplementation with indoles, should be explored further.

Acknowledgments

We thank Dr. Daniel Ziegler for purified pig liver FMO1 and rabbit anti-hog liver FMO1, Dr. Mark Shigenaga for (S)-5-3H-nicotine, Bioresponse L.L.C. for DIM, Dr. Mei-Fei Yueh for assistance in performing the animal work, and Sandy Segna for her editorial assistance.

Footnotes

  • Send reprint requests to: Dr. David E. Williams, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331-6602. E-mail:David.Williams{at}orst.edu

  • ↵1 A portion of this work was presented at the Society of Toxicology annual meeting, 1999, New Orleans, LA (abstract 1068).

  • This work was supported by U.S. Public Health Service Grants HL38650 (D.E.W.) and ES00834 (D.K.).

  • Abbreviations used are::
    I3C
    indole-3-carbinol
    CYP
    cytochrome P450
    FMO
    flavin-containing monooxygenase
    DIM
    3,3′-diindolylmethane
    DMA
    N,N-dimethylaniline
    ICZ
    indole[3,2-b]carbazole
    • Received January 28, 2000.
    • Accepted April 14, 2000.

References

  1. ↵
    1. Arnao MB,
    2. Sanchez-Bravo J,
    3. Acosta M
    (1996) Indole-3-carbinol as a scavenger of free radicals. Biochem Mol Biol Int 34:1125–1134.
    OpenUrl
  2. ↵
    1. Ayesh R,
    2. Al-Waiz M,
    3. Crothers J,
    4. Cholerton S,
    5. Mitchell SC,
    6. Idle JR,
    7. Smith RL
    (1988) Deficient nicotine N-oxidation in two sisters with trimethylaminuria. Br J Clin Pharmacol 25:664–665.
    OpenUrl
  3. ↵
    1. O'Neill IK,
    2. Chen J,
    3. Bartsch H
    1. Bailey GS,
    2. Dashwood RH,
    3. Fong AT,
    4. Williams DE,
    5. Scanlan RA,
    6. Hendricks JD
    (1991) Modulation of mycotoxin and nitrosamine carcinogenesis by indole-3-carbinol: Quantitative analysis of inhibition versus promotion. in Relevance to Human Cancer of N-Nitroso Compounds, eds O'Neill IK, Chen J, Bartsch H (IARC, Lyon), pp 275–280.
  4. ↵
    1. Bailey GS,
    2. Hendricks JD,
    3. Shelton DW,
    4. Nixon JE,
    5. Pawlowski NE
    (1987) Enhancement of carcinogenesis by the natural anticarcinogen indole-3-carbinol. J Natl Cancer Inst 78:931–934.
  5. ↵
    1. Berkman CE,
    2. Park SB,
    3. Wrighton SA,
    4. Cashman JR
    (1995) In vitro-in vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 50:565–570.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bjeldanes LF,
    2. Kim J-Y,
    3. Grose KR,
    4. Bartholmoew JC,
    5. Bradfield CA
    (1991) Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3- carbinol in vitro and in vivo: Comparison with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc Natl Acad Sci USA 88:9543–9547.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Bradfield CA,
    2. Bjeldanes LF
    (1987) Structure-activity relationships of dietary indoles: A proposed mechanism of action as modifiers of xenobiotic metabolism. J Toxicol Environ Health 21:31–35.
    OpenUrl
  8. ↵
    1. Cashman JR,
    2. Park SB,
    3. Yang Z-C,
    4. Wrighton SA,
    5. Jacob P III,
    6. Benowitz NL
    (1992) Metabolism of nicotine by human liver microsomes: Stereoselective formation of trans-nicotine N′-oxide. Chem Res Toxicol 5:639–646.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Cashman JR,
    2. Xiong Y,
    3. Lin J,
    4. Verhagen H,
    5. van Poppel G,
    6. van Bladeren PJ,
    7. Larsen-Su S,
    8. Williams DE
    (1999) In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles. Biochem Pharmacol 58:1047–1055.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Chen I,
    2. McDougal A,
    3. Wang F,
    4. Safe S
    (1998) Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19:1631–1639.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Cover CM,
    2. Hsieh SJ,
    3. Tran SH,
    4. Hallden G,
    5. Kim GS,
    6. Bjeldanes LF,
    7. Firestone GL
    (1998) Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273:3838–3847.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Crewe HK,
    2. Ellis SW,
    3. Lennard MS,
    4. Tucker GT
    (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171–178.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Damani LA,
    2. Pool WF,
    3. Crooks PA,
    4. Kaderlik RK,
    5. Ziegler DM
    (1988) Stereoselectivity in the N′-oxidation of nicotine isomers by flavin-containing monooxygenase. Mol Pharmacol 33:702–706.
    OpenUrlAbstract
  14. ↵
    1. Dashwood RH,
    2. Fong AT,
    3. Arbogast DN,
    4. Bjeldanes LF,
    5. Hendricks JD,
    6. Bailey GS
    (1994) Anticarcinogenic activity of indole-3-carbinol acid products: Ultrasensitive bioassay by trout microinjection. Cancer Res 54:3617–3619.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Dehal SS,
    2. Kupfer D
    (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402–3406.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Dehal SS,
    2. Kupfer D
    (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (Droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 27:681–688.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Fisher B,
    2. Costantino JP,
    3. Wickerham DL,
    4. Redmond CK,
    5. Kavanah M,
    6. Cronin WM,
    7. Vogel V,
    8. Robidoux A,
    9. Dimitrov N,
    10. Atkins J,
    11. Daly M,
    12. Wieand S,
    13. Tan-Chiu E,
    14. Ford L,
    15. Wolmark N
    (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Grubbs CJ,
    2. Steele VE,
    3. Casebolt T,
    4. Juliana MM,
    5. Eto I,
    6. Whitaker LM,
    7. Dragnev KH,
    8. Kelloff GJ,
    9. Lubet RL
    (1995) Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15:709–716.
    OpenUrlPubMed
  19. ↵
    1. Hayes AW
    1. Guengerich FP
    (1989) Analysis and characterization of enzymes. in Principles and Methods of Toxicology, ed Hayes AW (Raven Press, New York), pp 777–814.
  20. ↵
    1. Guengerich FP,
    2. MacDonald TL
    (1984) Chemical mechanism of catalysis by cytochrome P-450: A unified view. Acc Chem Res 17:9–16.
  21. ↵
    1. Guo D,
    2. Schut HAJ,
    3. Davis CD,
    4. Snyderwine EG,
    5. Bailey GS,
    6. Dashwood RH
    (1995) Protection by chlorophyllin and indole-3-carbinol against 2-amino-1-methyl-6- phenylimidazo [4,5-b] pyridine (PhIP)-induced DNA adducts and colonic aberrant crypts in the F344 rat. Carcinogenesis 16:2931–2937.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Hammond DK,
    2. Bjercke RJ,
    3. Langone JJ,
    4. Strobel HW
    (1991) Metabolism of nicotine by rat liver cytochrome P450. Assessment utilizing monoclonal antibodies to nicotine and cotinine. Drug Metab Dispos 19:804–808.
    OpenUrlAbstract
  23. ↵
    1. Hlavica P,
    2. Kunzel-Mulas U
    (1993) Metabolic N-oxide formation by rabbit-liver microsomal cytochrome P-4502B4: Involvement of superoxide in the NADPH- dependent N-oxygenation of N,N-dimethylaniline. Biochim Biophys Acta 1158:83–90.
    OpenUrlPubMed
  24. ↵
    1. Jordan VC
    (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507–571.
    OpenUrlPubMed
  25. ↵
    1. Jordan VC,
    2. Collins MM,
    3. Rowsby L,
    4. Prestwich G
    (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305–316.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Killackey MA,
    2. Hakes TB,
    3. Price VK
    (1985) Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237–238.
    OpenUrlPubMed
  27. ↵
    1. Kojima T,
    2. Tanaka T,
    3. Mori H
    (1994) Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res 54:1446–1449.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Larsen-Su S
    (1998) Developmental and dietary regulation of flavin-containing monooxygenase. Ph.D. Thesis, Oregon State University.
  29. ↵
    1. Larsen-Su S,
    2. Williams DE
    (1996) Dietary indole-3-carbinol inhibits FMO activity and the expression of flavin-containing monooxygenase form 1 in rat liver and intestine. Drug Metab Dispos 24:927–931.
    OpenUrlAbstract
  30. ↵
    1. Lowry OH,
    2. Rosebrough NJ,
    3. Farr AL,
    4. Randall RJ
    (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
    OpenUrlFREE Full Text
  31. ↵
    1. Mani C,
    2. Hodgson E,
    3. Kupfer D
    (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen: II: Flavin-containing monooxygenase-mediated N- oxidation. Drug Metab Dispos 21:657–661.
    OpenUrlAbstract
  32. ↵
    1. Mani C,
    2. Kupfer D
    (1991) Cytochrome P450-mediated activation and irreversible binding of the antioestrogen tamoxifen to proteins in rat and human liver: Possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 51:6052–6058.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Manson MM,
    2. Hudson EA,
    3. Ball HWL,
    4. Barrett MC,
    5. Clark HL,
    6. Judah DJ,
    7. Verschoyle RD,
    8. Neal GE
    (1998) Chemoprevention of aflatoxin B1-induced carcinogenesis by indole-3-carbinol in rat liver—predicting the outcome using early biomarkers. Carcinogenesis 19:1829–1836.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. McDanell R,
    2. McLean AE,
    3. Hanley AB,
    4. Heaney RK,
    5. Fenwick GR
    (1988) Chemical and biological properties of indole glucosinolates (glucobrassicin): A review. Food Chem Toxicol 26:59–70.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Messina ES,
    2. Tyndale RF,
    3. Sellers EM
    (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608–1614.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Morse MA,
    2. LaGreca SA,
    3. Amin SG,
    4. Chung FL
    (1990) Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and on the metabolism and disposition of NNK in A/J mice. Cancer Res 50:2613–2617.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Nakajima M,
    2. Yamamoto T,
    3. Nunoya K-I,
    4. Yokoi T,
    5. Nagashima K,
    6. Inoue K,
    7. Funae Y,
    8. Shimada N,
    9. Kamataki T,
    10. Kuroiwa Y
    (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212–1217.
    OpenUrlAbstract
  38. ↵
    1. Pandey RN,
    2. Armstrong AP,
    3. Hollenberg PF
    (1989) Oxidative N-demethylation of N,N-dimethylaniline by purified isozymes of cytochrome P-450. Biochem Pharmacol 38:2181–2185.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Park SB,
    2. Jacob P III,
    3. Benowitz NL,
    4. Cashman JR
    (1993) Stereoselective metabolism of (S)-(−)-nicotine in humans: Formation of trans-(S)-(−)-nicotine N-1′-oxide. Chem Res Toxicol 6:880–888.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Pianezza ML,
    2. Sellers EM,
    3. Tyndale RF
    (1998) Nicotine metabolism defect reduces smoking. Nature (Lond) 393:750.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Poon GK,
    2. Walter B,
    3. Lonning PE,
    4. Horton MN,
    5. McCague R
    (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos 23:377–382.
    OpenUrlAbstract
  42. ↵
    1. Seto Y,
    2. Guengerich FP
    (1993) Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P450 2B1. J Biol Chem 268:9986–9997.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Shehin-Johnson SE,
    2. Williams DE,
    3. Larsen-Su S,
    4. Stresser DM,
    5. Hines RN
    (1995) Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit. J Pharmacol Exp Ther 272:1293–1299.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Shigenaga MK,
    2. Jacob P III,
    3. Benowitz NL,
    4. Castagnoli N, Jr,
    5. Trevor AJ
    (1987) Synthesis of (S)-5-3H-nicotine and (S)-5-3H-cotinine. J Labelled Compds 14:919–934.
    OpenUrl
  45. ↵
    1. Houlihan WJ
    1. Spande TF
    (1979) Hydroxyindoles, indoles, alcohols and indolethiols. in Indoles, part 3, ed Houlihan WJ (John Wiley & Sons, Inc. New York), pp 1–355.
  46. ↵
    1. Stresser DM,
    2. Bailey GS,
    3. Williams DE
    (1994a) Indole-3-carbinol and beta-naphthoflavone induction of aflatoxin B1 metabolism and cytochrome P450 associated with bioactivation and detoxification of aflatoxin B1 in the rat. Drug Metab Dispos 22:383–391.
    OpenUrlAbstract
  47. ↵
    1. Stresser DM,
    2. Bjeldanes LF,
    3. Bailey GS,
    4. Williams DE
    (1995a) The anticarcinogen 3,3′-diindolylemthane is an inhibitor of cytochrome P450. J Biochem Toxicol 10:191–201.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Stresser DM,
    2. Williams DE,
    3. Griffin DA,
    4. Bailey GS
    (1995b) Mechanisms of tumor modulation by indole-3-carbinol: Disposition and excretion in male Fischer 344 rats. Drug Metab Dispos 23:965–975.
    OpenUrlAbstract
  49. ↵
    1. Stresser DM,
    2. Williams DE,
    3. McLellan LI,
    4. Harris TM,
    5. Bailey GS
    (1994b) Indole-3-carbinol induces a rat liver glutathione transferase subunit (Yc2) with high activity toward aflatoxin B1 exo-epoxide: Association with reduced levels of hepatic aflatoxin-DNA adducts in vivo. Drug Metab Dispos 22:392–399.
    OpenUrlAbstract
  50. ↵
    1. Towbin H,
    2. Staehelin T,
    3. Gordon J
    (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Umemoto A,
    2. Monden Y,
    3. Komaki K,
    4. Suwa M,
    5. Kanno Y,
    6. Suzuki M,
    7. Lin C-X,
    8. Ueyama Y,
    9. Momen MA,
    10. Ravindernath A,
    11. Shibutani S
    (1999) Tamoxifen-DNA adducts formed by α-acetoxytamoxifen N-oxide. Chem Res Toxicol 12:1083–1089.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Wattenberg LW
    (1977) Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothicyanate and related compounds. J Natl Cancer Inst 58:395–398.
  53. ↵
    1. Hlavica P,
    2. Damani LA
    1. Williams DE
    (1991) Factors regulating the activity of the rabbit lung flavin containing monooxygenase. in N-Oxidation of Drugs: Biochemistry, Pharmacology and Toxicology, eds Hlavica P, Damani LA (Chapman & Hall, New York), pp 91–105.
  54. ↵
    1. Williams DE,
    2. Ding X,
    3. Coon MJ
    (1990b) Rabbit nasal cytochrome P-450 NMa has high activity as a (S)-nicotine oxidase. Biochem Biophys Res Commun 166:945–952.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Williams DE,
    2. Reed RL,
    3. Kedzierski B,
    4. Dannan GA,
    5. Guengerich RP,
    6. Buhler DR
    (1989) Bioactivation and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat liver. Drug Metab Dispos 17:387–392.
    OpenUrlAbstract
  56. ↵
    1. Williams DE,
    2. Shigenaga MK,
    3. Castagnoli N, Jr
    (1990a) The role of cytochromes P- 450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung. Drug Metab Dispos 18:418–428.
    OpenUrlAbstract
  57. ↵
    1. Williams GM,
    2. Iatropoulos MJ,
    3. Djordjevic MW,
    4. Kaltenberg OP
    (1993) The triphenylethylene drug tamoxifen is a strong carcinogen in the rat. Carcinogenesis 14:315–317.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Wong GY,
    2. Bradlow L,
    3. Sepkovic D,
    4. Mehl S,
    5. Mailman J,
    6. Osborne MP
    (1997) Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 28–29:111–116.
  59. ↵
    1. Wortelboer HM,
    2. de Kruif CA,
    3. Van Iersel AAJ,
    4. Falke HE,
    5. Noordhoek J,
    6. Blaauboer BJ
    (1992a) Acid reaction products of indole-3-carbinol and their effects on cytochrome P450 and phase II enzymes in rat and monkey hepatocytes. Biochem Pharmacol 43:1439–1447.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Wortelboer HM,
    2. van der Linden ECM,
    3. de Kruif CA,
    4. Noordhoek J,
    5. Blaauboer BJ,
    6. van Bladeren PJ,
    7. Falke HE
    (1992b) Effects of indole-3-carbinol on biotransformation enzymes in the rat: In vivo changes in liver and small intestinal mucosa in comparison with primary hepatocyte cultures. Food Chem Toxicol 30:589–599.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Ziegler DM
    (1993) Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 33:179–199.
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Concurrent Flavin-Containing Monooxygenase Down-Regulation and Cytochrome P-450 Induction by Dietary Indoles in Rat: Implications for Drug-Drug Interaction

Sirinmas Katchamart, David M. Stresser, Shangara S. Dehal, David Kupfer and David E. Williams
Drug Metabolism and Disposition August 1, 2000, 28 (8) 930-936;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section